New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareDecapeptide-12 vs Cagrilintide

Decapeptide-12 vs Cagrilintide

Side-by-side comparison of key properties, dosing, and research.

Skin & Cosmetic
Decapeptide-12
GLP-1 / Weight Loss Agonists
Cagrilintide
Summary
Decapeptide-12 is a synthetic 10-amino acid peptide developed for skin brightening and depigmentation. It selectively inhibits tyrosinase activity and downstream melanogenesis pathways, reducing hyperpigmentation, dark spots, and uneven skin tone without the irritation associated with hydroquinone.
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells. Cagrilintide slows gastric emptying, suppresses glucagon, and reduces appetite via central amylin receptors. In combination with semaglutide (CagriSema), Phase 2 trials achieved approximately 15% body weight reduction. Phase 3 trials (REDEFINE program) are ongoing.
Half-Life
Not applicable (topical)
~7–10 days
Admin Route
Topical
SubQ
Research
Typical Dose
5 ppm (0.0005%) concentration
0.16 mg → 0.3 mg → 0.6 mg → 1.2 mg → 2.4 mg
Frequency
Twice daily (AM and PM)
Once weekly
Key Benefits
  • Reduces hyperpigmentation and dark spots
  • Evens skin tone and improves radiance
  • Inhibits post-inflammatory hyperpigmentation
  • Well-tolerated alternative to hydroquinone
  • Effective for melasma and age spots
  • Non-cytotoxic to melanocytes
  • ~15% body weight reduction in combination with semaglutide (CagriSema Phase 2)
  • Synergistic appetite suppression complementing GLP-1 receptor agonists
  • Reduces post-meal glucagon excursions improving glycemic control
  • Slows gastric emptying contributing to prolonged satiety
  • Once-weekly dosing via subcutaneous injection
  • Potential for greater weight loss than semaglutide monotherapy
Side Effects
  • Generally very well-tolerated
  • Rare mild irritation or sensitivity in some skin types
  • Results may take several weeks to become visible
  • Nausea (most common, especially during titration)
  • Vomiting
  • Decreased appetite
  • Diarrhea
  • +2 more
Stacks With